Stock Indices Waver on Strength in Chipmakers vs Weakness in Software Companies

Sandisk is up more than 10% to lead S&P 500 and Nasdaq 100 gainers, making it a standout single-name driver in the wrap.

Potential continuation in the very near term, but expect volatility given the magnitude of the move.

The article reports the magnitude and leadership but does not provide the underlying catalyst, limiting conviction on follow-through.

Western Digital is up more than 7% as part of the chipmaker/AI-infrastructure strength supporting the broader market.

Mild positive near-term bias tied to sector momentum rather than company-specific fundamentals in this text.

The move is explicitly tied to the day’s chipmaker strength; no separate WDC-specific news is disclosed.

Marvell Technology is up more than 7% alongside other AI-infrastructure names, reinforcing the sector’s relative strength today.

Near-term upside sensitivity to continued AI-infrastructure momentum.

The article links MRVL’s gain to the broader chipmaker/AI-infrastructure bid, without detailing a separate MRVL catalyst.

Datadog is down more than 3% to lead Nasdaq 100 losers, signaling software weakness weighing on the overall market.

Near-term downside pressure likely to persist if software selling continues.

The article provides the magnitude and relative leadership on the day, but no DDOG-specific catalyst is included.

Adobe Systems is down more than 3% as part of broad software weakness limiting gains in the overall market.

Negative near-term bias if the software complex remains under pressure.

The text frames ADBE’s move as part of software weakness; it does not disclose a new ADBE driver.

ServiceNow is down more than 3%, explicitly cited among software laggards that are capping broader index upside.

Near-term downside sensitivity while software remains the drag.

The article reports NOW’s magnitude and sector context but provides no NOW-specific news catalyst.

EyePoint is down more than 71% after saying its experimental eye-disease treatment failed its primary goal in a late-stage trial.

Further downside risk and elevated volatility are likely until investors digest next steps and pipeline implications.

The article includes a clear primary-goal failure in a late-stage trial, which is typically material and time-sensitive for biotech pricing.

Constellation Brands is down more than 5% after Berkshire Hathaway announced it liquidated its holdings in the company.

Potential continued weakness while the market reassesses positioning and any implied demand outlook.

The article provides the ownership liquidation event and the immediate price reaction, but not the rationale behind Berkshire’s move.